Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.
Robert Andtbacka, MD, an assistant professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine and a surgeon and investigator with Intermountain Healthcare and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.
In a randomized phase III clinical trial, T-VEC was compared to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresected stage IIIB, IIIC, or IV melanoma.
The primary endpoint of this trial, a durable response rate lasting six months or longer, was met. In the T-VEC arm, 16% of patients had a durable response lasting six months or longer, compared to 2% in the GM-CSF arm.
The secondary endpoint of the trial was overall survival. There was a planned interim analysis of overall survival when 85% of a planned 290 events had been met. In the interim analysis, a trend to improvement in survival was observed. Andtbacka says a final analysis will be available later this year.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More